Press Releases

Curis to Present at the 13th Annual BIO Investor Forum

LEXINGTON, Mass., Oct. 3, 2014 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused biotechnology company developing novel drug candidates for the treatment of human cancers, today announced that the Company will present at the 13th Annual BIO Investor Forum at 8:00 am PDT on Tuesday, October 7, 2014 in San Francisco, CA.

Dr. Ali Fattaey, President and Chief Executive Officer, will provide an overview of Curis' proprietary cancer programs including its dual histone deacetylase (HDAC) and phosphoinositide 3-kinase (PI3K) inhibitor, CUDC-907, and its antagonist of inhibitor of apoptosis (IAP) proteins, CUDC-427. Dr. Fattaey will also provide an overview of Curis' partnered programs including Erivedge® (vismodegib), a hedgehog pathway inhibitor developed under collaboration with Genentech and Roche that is the only approved medicine for patients with advanced basal cell carcinoma, and Debio 0932, an HSP90 inhibitor under collaboration with Debiopharm.

A corresponding webcast of the presentation can be accessed by visiting:

http://www.veracast.com/webcasts/bio/investorforum2014/40100192.cfm

The webcast will be archived shortly after the live events and available for 90 days following each conference, and also available for 30 days on the Investor Relations section of the Curis website at www.curis.com.

About Curis, Inc.

Curis is an oncology-focused biotechnology company developing novel drug candidates for the treatment of human cancers. Curis' pipeline of drug candidates includes CUDC-907, a dual HDAC and PI3K inhibitor, and CUDC-427, a small molecule antagonist of IAP proteins. Curis is also engaged in a collaboration with Genentech, a member of the Roche Group, under which Genentech and Roche are developing and commercializing Erivedge®, the first and only FDA-approved medicine for the treatment of advanced basal cell carcinoma. Curis partner Debiopharm is studying HSP90 inhibitor, Debio 0932 in patients with advanced lung cancer. For more information, visit Curis' website at www.curis.com.

CONTACT: For More Information:

         Mani Mohindru, Ph.D.

         Vice President, Corporate Strategy and Investor Relations

         Curis, Inc.

         617-503-6605

         mmohindru@curis.com

         

         Michael P. Gray

         Chief Business and Chief Financial Officer

         Curis, Inc.

         617-503-6632

         mgray@curis.com